For over two decades, OncoEMR has brought gold standard technology to community oncology, one of medicine's most complex, protocol-driven specialties. Flatiron is now bringing that same infrastructure to independent urology, developed in direct partnership with practicing urologists. Now enabling over 16K urology visits weekly across a growing network of urology practices, OncoEMR for Urology streamlines high-volume care and long-term protocols, helping urologists see more patients and run a healthier practice. Meet our urology product, clinical and workflow leads for a hands-on demo at the LUGPA Annual Meeting, Nov 5-7 in Chicago IL. Register for your live demo here: https://lnkd.in/dZRzeZ3i
Flatiron Health
Biotechnology Research
New York, New York 101,795 followers
Reimagining the infrastructure of cancer care
About us
Flatiron Health’s mission is to improve and extend lives by learning from the experience of every person with cancer.
- Website
-
http://www.flatiron.com
External link for Flatiron Health
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- New York, New York
- Type
- Privately Held
Locations
-
Primary
Get directions
233 Spring St
5th Floor
New York, New York 10013, US
Employees at Flatiron Health
Updates
-
In academic oncology research, the best ideas often lose to time. A team identifies a promising question, then spends months securing, cleaning and validating data. By the time the dataset is ready, another group has already published. Flatiron Health partners with academic medical centers and health systems to shorten that path. Through these partnerships, research teams gain access to research-ready oncology real-world data, so investigators can move from concept to publication faster and answer oncology’s most important questions first. Schedule time to meet Flatiron’s partnerships team at Becker’s Oncology Executive Summit Nov 4 & 5 to learn how your institution can participate: https://lnkd.in/dgx2ds5W #AcademicMedicine #HealthSystems #Oncology #RealWorldData #RWE Emily Castellanos | Becker's Healthcare
-
-
Real-world data has long helped clinical development teams better understand patients, treatment patterns, and outcomes. AI is expanding what’s possible. By learning from large, longitudinal datasets, AI is turning RWD from a retrospective resource into a forward-looking one. Approaches like digital twins can estimate likely outcomes under different scenarios, providing additional context for trial design and interpretation and helping teams make more confident decisions. Our latest blog explores how these advances are creating new opportunities for clinical development teams to make better use of real-world evidence. Read more: https://lnkd.in/dYpTyrQZ
-
-
Real-world data is clinically valuable. At #DGHO2026, three observations stood out in our conversations with the German oncology community: • Detailed, structured data answers questions other sources can't. With structured data, you can understand how and why treatments change, such as dose modifications and therapy adjustments. In a rapidly evolving field, getting this data in weeks rather than months makes a difference. • AI is changing how we work with data. Flatiron Telescope lets clinical and research teams ask questions in plain language and get answers without coding. They can now test their own hypotheses instead of waiting for an analyst. • High quality EHR-derived real-world data can and should inform evidence dossiers for HTA. Dr. Maike Sauer explains why https://lnkd.in/gGzVbGam here.
-
-
What does it take to turn healthcare innovation into lasting commercial success? For Flatiron Health, that means connecting advances in technology and data with the real needs of clinicians, researchers, and patients, and ensuring innovation delivers value beyond its initial promise. On November 3, our CEO Nathan Hubbard will join leaders from across healthcare and biopharma at Longwood Healthcare Leaders' #BostonCEO event for a discussion on "Positioning for Commercial Success." We look forward to contributing Flatiron's perspective on building and scaling solutions that make a meaningful difference in healthcare. Learn more: https://lnkd.in/eehfZ2xB
-
-
How is biopharma actually using AI for oncology research? From curating real-world data to scaling complex analyses, AI is creating new opportunities for researchers—but realizing that potential requires high-quality data and rigorous validation. On November 4, join Flatiron Health and Endpoints News for a live webinar on how biopharma is putting AI to work in oncology research, and what it takes to generate trustworthy evidence at scale. Christopher Mader, Flatiron's Head of Strategy, will be joined by industry experts from Genentech, Azurity Pharmaceuticals, and Orion Pharma for this wide-ranging discussion. You'll hear: - How validated real-world data supports trustworthy AI-enabled research - How transparent validation is used to build trust in real-world insights - How pharma is scaling analyses and uncovering new insights with AI 📅 Wednesday, November 4 | 11am ET 🔗 Register here -> https://lnkd.in/dm6ikdKa #AI #RealWorldEvidence #Oncology #HEOR
-
At ESMO, our team – Christoph Buhl, Sascha van Boemmel-Wegmann, MS, PhD, Daniela Zuluaga Lotero, and Lars Galonska – presented new multinational real-world research examining how metastasis-directed therapy is used in colorectal cancer across Germany, Japan, and the UK. Great to see this work shared with the global oncology community and contributing to conversations about differences in cancer care across countries. Read the research: https://lnkd.in/g4gH_cxD #ESMO2026 #RealWorldEvidence #ColorectalCancer
-
-
We’re proud to see Flatiron Germany's contribution to two significant studies presented at #ESMO2026! Our international data network, spanning the US, UK, Germany, and Japan, is enabling life sciences partners to understand how cancer treatment patterns and patient outcomes differ across markets. Our colorectal cancer research: https://lnkd.in/g4gH_cxD Our NSCLC research: https://lnkd.in/gvtq4MEi
💡🇪🇸 I'm looking forward to attending #ESMO2026 in Madrid this weekend, where we will share two insightful studies using Flatiron data from our patient networks in the US, UK, Germany and Japan. 🔸 Metastatic #ColorectalCancer (907eP): We mapped how metastasis-directed therapy (metastasectomy/ablation) is used before first progression in Germany, Japan, and the UK: uptake, timing (picture 1) vs systemic therapy, and what happens after MDT. Findings: Uptake and sequencing differ clearly by country, but similar time to progression from first MDT across markets. 🔹 Metastatic #NSCLC (2855eP) We looked at baseline serum sodium (sNA) in patients starting first-line immune checkpoint inhibitors in the US, UK, and Germany. Findings: Hyponatremia is common; in adjusted analyses the association with real-world survival is clearest in the large US cohort (KM plot in picture 2), with directionally consistent patterns in the European cohorts. Our findings align with previous research and suggest sNa as a "simple" lab marker for risk stratification. Further research in other treatment cohorts is warranted. If you’re at the congress, search the e-posters under 907eP and 2855eP. I’d be glad to connect & discuss! These were fantastic team efforts with Markus Knott, Daniela Zuluaga Lotero, Lars Galonska, Dirk Plewe, Christoph Buhl, Patrycja Pluta, Izumi Nasu, Arun Sujenthiran MD, Emily Castellanos and all our Flatiron colleagues in Berlin, London, Tokyo, and New York who were involved in procuring the data! #RealWorldEvidence #RWE #RealWorldData #Oncology #ImmunoOncology
-
-
How can insights from everyday cancer care help shape the next clinical trial and inform care for the next patient? Following her conversation with Damian Garde at the STATSummit, our Chief Product Officer, Kate Estep, shares how AI can accelerate that learning, and why validated data, oncology expertise, and tools that fit into daily workflows are essential to making it happen. Read her perspective below.
Roughly 7% of adult cancer patients in the U.S. ever enroll in a clinical trial. The industry designs and approves therapies based on that evidence, then hands those medicines to oncologists treating the remaining 93%. And those patients represent a clinical reality that trial protocols rarely capture. Last week at the STAT Summit, Damian Garde and I sat down to talk about why closing that gap has taken decades, and what the future holds. Having spent my career building EHRs and real-world evidence products, I’ve watched healthcare chase the idea of a self-learning system. The intent was right, but the mechanics were punishingly slow. A patient’s story unfolds across unstructured documentation. Structuring that narrative across millions of patients was rate-limited by capacity and time. Answering a basic trial feasibility question could take six months, while standards of care were shifting in real time. AI fundamentally alters that timeline. We are generating research-grade evidence from millions of patients and asking questions about clinical patterns that happened yesterday instead of 6 months ago. Protocol assumptions that once stalled development teams for weeks can be interrogated in an afternoon. Realizing impact from this speed requires systems built around four principles: Validated Data & Semantic Foundations: Building dependable evidence requires an AI platform grounded in millions of diverse patient journeys from care settings around the world, layered with deep oncology knowledge: how lines of therapy are assigned, how biomarker panels shift, and how disease actually progresses. To trust the output, that entire layer must be benchmarked against clinician review and proven against clinical reality. Continuous Intelligence: The era of waiting six months for retrospective data pulls is over. Speed in modern oncology demands continuous intelligence: an interactive, real-time environment where teams can rapidly test assumptions, refine cohorts, and answer strategic questions at the pace they actually arise. Flexible Workflow Integrations: Algorithms only create impact when integrated into workflows. Technology must fit how teams work, whether through a self-serve interface for interactive exploration or direct integration into existing enterprise data platforms. This requires great design and a deep understanding of customers. Precision Care Enablement: Generalized guidance rarely tells the whole story for the specific patient in the exam room. Effective systems deliver trusted insights into clinical workflows, measure whether outcomes improve, and feed that learning back so every patient’s care makes the next patient’s care better. When those pieces connect, you get compounding intelligence instead of isolated projects. Every patient treated refines the next trial, and every trial insight flows back to inform bedside care in weeks rather than years. Thank you to Damian and STAT for a great conversation!
-
-
Prostate cancer affects nearly 160 men in the UK every day. Yet, critical information is often held back by fragmented patient data. Biomarker results, imaging scans, and other vital clinical information sit scattered across different hospital systems, limiting access to insights that could transform outcomes. 🧩 To address this issue, we launched our own UK Prostate Cancer Panoramic dataset: a new window into prostate cancer care, built from nearly 14,000 patients longitudinal journeys across UK NHS Trust cancer centers. Our dataset captures: • Full disease spectrum coverage (from diagnosis through advanced disease) • Comprehensive treatment histories across all therapy types • Advanced biomarker and diagnostic data (HRR testing, PSMA-PET imaging, PSA measurements) • Real-world clinical outcomes and survival data Learn more about this dataset: https://lnkd.in/dryrpzAP
-
